The tumour-suppressor gene BRCA2 has been demonstrated to be involved in maintenance of genome integrity by affecting DNA double-strand break repair and homologous recombination. Protein-truncating mutations in BRCA2 predispose women to early onset breast and ovarian cancers and account for 15-30% of familial breast cancer risk. In contrast, the human cancer risk due to missense mutations, intronic variants, and in-frame deletions and insertions in the BRCA2 gene, called unclassified variants, has not been determined. Here, we want to define if the yeast Saccharomyces cerevisiae is a good model to study the role of BRCA2 in DNA recombination and repair and to characterise the unclassified BRCA2 missense variants. Therefore, we expressed the wild-type BRCA2 in yeast and determined the effect of BRCA2 on yeast homologous recombination, methyl methanesulphonate (MMS)-induced Rad51 and Rad52 foci and MMS sensitivity. The expression of BRCA2 induces a high increase in both intra-and inter-recombination events and confers a higher MMS resistance as compared with the negative control. This may suggest that BRCA2 gets involved in DNA repair pathways in yeast. Moreover, the expression of BRCA2 did not affect the number of cells carrying Rad51 or Rad52 nuclear foci. Finally, we aimed to investigate if yeast could be reliable system to set up a functional assay to distinguish a mutated protein from a neutral polymorphism. Therefore, we have expressed two neutral (M1915T and A2951T) and one pathogenic variant (G2748D) in yeast and checked the effect on recombination. The neutral M1915T variant increased intra-chromosomal recombination by almost 2-fold and the other neutral A2975T variant increased intra-chromosomal recombination 2.5-fold as compared with the control. On the other end, the pathogenic variant G2748D did not increase intra-and inter-chromosomal recombination in yeast and, consequently, confers a phenotype very different from the wild-type BRCA2. Moreover, we have also evaluated whether the expression of the selected unclassified variants affects homologous recombination in yeast. Results indicated that the expression of the selected BRCA2 variants differentially affects yeast recombination suggesting that yeast could be a very promising genetic system to characterise BRCA2 missense variants.
Introduction
Breast cancer is the most common malignant neoplasia of women in the western world affecting approximately 6 out of 100 women before the age of 74. About 80% of breast cancers are sporadic and are diagnosed in women without any familial aggregation. However, the remaining cases are inheritable and about 40% of those are caused by mutations in one of the two tumour-suppressor genes, BRCA1 (Breast Cancer 1) and BRCA2 (Breast Cancer 2) (1, 2). Inherited mutations in BRCA2 have been associated with an increased lifetime risk of breast cancer. There are hundreds of deleterious germline mutations found in BRCA2 that give rise to truncated non-functional protein. However, the pathological consequence of many missense mutations, also called 'unknown classified variants' (UCVs), found in breast and/or ovarian cancer families, remains to be ascertained, posing a problem for patients and their health care providers. UCVs account for over 35% of all reported mutations in BRCA1 and approximately 50% of BRCA2 (Breast Cancer Information Core Database: http://research.nhgri.nih.gov/bic/).
The BRCA2 protein provides an important function in promoting homologous recombination (HR) repair of damaged DNA in cells, presumably through its interaction with the RAD51 recombinase, which may underlay its role in tumour suppression (3) (4) (5) (6) . Human BRCA2 protein contains several functional domains and although the role of the N-terminal domain of the protein is uncertain, the central part (about 1000 amino acids) of BRCA2 contains eight BRC repeats that bind RAD51 (5, 7) ( Figure 1 ). Structural analysis revealed five distinct domains in the BRCA2 C-termini. The first domain comprises 190 amino acids consisting of mainly α-helices, termed the helical domain. This is followed by the three structurally related domains of approximately 110 amino acids (OB1, OB2 and OB3; (aa 2620-3184) that exhibit homology and structural similarity to the OB (oligonucleotide/oligosaccharide-binding)-fold that is present in most prokaryotic and eukaryotic ssDNAbinding proteins, including SSB (ssDNA-binding protein) and RPA (replication protein A) ( Figure 1 ). Consistent with the presence of three OB-fold domains, the BRCA2 C-terminal fragment was shown to bind with high affinity to single-and double-stranded DNA (8, 9) .
The functional assays available for UCV testing on BRCA2 are based on mammalian cell cultures transfected with plasmid vectors expressing the mutated BRCA2 to evaluate the efficiency of DNA double-strand breaks repair by HR or the survival to genotoxic agents as compared with the wild-type protein (10) (11) (12) . All those assays are labour intensive and time consuming; the recently proposed computational classification of UCVs can significantly reduce the time by identifying the UCVs most likely to be deleterious, but still need to be supported by functional studies (13) .
The budding yeast Saccharomyces cerevisiae represents a powerful genetic model: this organism is easy to grow and genetically manipulate. The expression of human wild-type BRCA1 in the yeast S. cerevisiae inhibits growth, conferring a small-colony phenotype has been exploited to characterise several UCVs (14) . Moreover, the expression of mutated BRCA1 protein in the yeast S. cerevisiae appears to increase HR (15) . Therefore, yeast can be used as model organism to distinguish the deleterious from neutral mutations.
In this study, we expressed the wild-type BRCA2 in yeast and analysed the effect on HR. Moreover, we have studied the effect of BRCA2 on rad51 and rad52 nuclear foci induced by MMS to test whether BRCA2 could affect DNA damage repair in yeast. Finally, we expressed several missense BRCA2 variants and investigated whether yeast could be a promising system to develop as functional assay to characterise the UCVs.
Materials and methods

Plasmids and DNA manipulation
The plasmid pYES2-BRCA2, which contains the human BRCA2 gene under the galactose-inducible promoter pGAL1, was constructed from pcDNA3-BRCA2 (a gift from Chris Lord) as follows: BRCA2 was cut out from the vector with KpnI and ApaI and cloned in the yeast expression vector pYES2 (Invitrogen) after restriction using KpnI and EcoRI. The correct frame of the human BRCA2 cDNA was checked by DNA sequence analysis. Plasmids carrying the BRCA2 missense variants (selected as described below) and the controls were constructed by site-directed mutagenesis with specific oligonucleotides using QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The primer sequence is available upon request. Plasmid DNA preparation was carried out using the Wizard miniprep kit (Promega, Madison, WI, USA). The mutations were checked by DNA sequence analysis. The plasmid pWJ1344 (from Rodney Rothstein (16) (17) (18) ), carrying the RAD52-YFP, was used to assess the effect of BRCA2 on Rad52 nuclear foci.
BRCA2 missense variant selection
DNA samples from individuals belonging to 505 breast and/or ovarian cancer families, collected at the University Hospital of Pisa, were previously analysed for BRCA1 and BRCA2 germline mutations using an automated DNA sequencer (ABI 3130 XL; Applied Biosystems). The selection criteria for the individuals recruited were as follows: 1) occurrence of two or more cases of breast and/or ovarian cancer in first-or second-degree relatives 2) early onset of the disease 3) occurrence of bilateral breast cancer or occurrence of breast and ovarian cancers in the same individual.
Of 505 breast and/or ovarian cancer families, we have selected 343 patients negative for BRCA1/2 mutation carriers of 83 novel and previously described variants of BRCA2. Out of these 83, we have selected 40 missense UCVs, excluding synonymous and intronic variants. Among these 40 missense UCVs, we have chosen eight variants that are not previously described or classified in other papers (S286P, M927V,T1011R, L1019V, N1878K, S2006R, R2108C and V3091I). Moreover, we have chosen four variants as controls: we have selected the G2748D as pathogenic control (Table I , (19, 20) ); the variants M1915T and A2951T have been chosen as neutral controls (Table I, (10, 20, 21) ). The S286P variant maps near the N-terminus; the M927V variant is located before the BRC repeat domain ( Figure 1) ; the variants T1011R, L1019V, N1878K and S2006R are localised in the BRC repeat domain ( Figure 1) ; the R2018C is located right after the BRC repeats in the BRAF35 interaction domain (Figure 1 ), the V3091I variant is located in the OB-fold ssDNA binding domain (Figure 1 ). Moreover, we have constructed specific vectors to express the BRCA2 neutral variants M1915T and A2951T (Figure 1 underlined, Table I ) and the deleterious G2748D (Figure 1 in bold, Table I ).
In order to identify whether non-synonymous amino acid changes are likely to disrupt BRCA2 gene functions, we used three comparative evolutionary bioinformatics programs: Sorting Intolerant From Tolerant (SIFT; http://blocks.fhcrc.org/sift/SIFT.html, (22) ), Polymorphism Phenotyping (PolyPhen; http://tux.emblheidelberg.de/ramensky/pilyphen.cgi, (23) ) and Align-GVGD (http://agvgd.iarc.fr/agvgd_input.php, (24) ). SIFT is a multiple sequence alignment tool based on the premise that important amino acids will be conserved amongst species in a protein family in such a way that changes of amino acids conserved in the family should affect protein function (22) . PolyPhen is an automatic tool for the prediction of the possible impact an amino acid substitution could have on the structure and function of a human protein (23) . Align-GVGD, which compares different sequences by simple alignment, is a mathematically simple missense substitution analysis algorithm, based on the Grantham difference, which measures the biochemical differences between pairs of amino acids (25) . This method predicts variants in the query sequence based on a combination of Grantham Variation (GV), which measures the amount of observed biochemical evolutionary variation at a particular position in the alignment, and Grantham Deviation (GD), which measures the biochemical difference between the reference and amino acid encoded by the variant (24, 26) . The missense variants are described in Table I . The haploid yeast strain W8702 (MATa, YFP-RAD51 trp1, leu2, ura-52 (from Rodney Rothstein) was used to determine the effect of BRCA2 expression on DNA damage-induced RAD51 nuclear foci. The haploid yeast strain RSY12 (MATa leu2-3,112 his3-11,15 URA3::HIS3) was transformed with pWJ1344 and therefore used to determine the effect of BRCA2 expression on DNA damage-induced RAD52 nuclear foci. Media preparation and yeast culturing were carried out according to standard techniques. Yeast was transformed with plasmid DNA using the lithium acetate method with single-stranded DNA as carrier, following the procedure described in (27) . Transformants were selected in solid medium lacking uracil (SC-URA). Colonies were grown for 4 days at 30°C and analysed further.
Yeast strain
RT-PCR, yeast protein extraction and immune precipitation
In order to verify the expression of BRCA2 mRNA in yeast, independent yeast clones carrying the BRCA2 expression vector were grown in 5 ml -URA for 24 h at 30°C. Then, the cultures were split into two aliquots, one in galactose for high BRCA2 induction and the other one in glucose as negative control, and incubated for 4 h at 30°C under shaking. Total RNA was extracted from yeast clones following the standard procedure (28) . Reverse-transcriptasepolymerase chain reaction (RT-PCR) was performed with 1 µg of total RNA using the SuperScript® II First-Strand Synthesis System for RT-PCR (Invitrogen). The primers forward and reverse located in two regions of BRCA2 are available upon request.
The level of BRCA2 protein was measured in the RS112 strain expressing the BRCA2-pYES2 or the UCV-BRCA2 variant. Single clones were grown in 100 ml of SC-URA galactose medium at 30°C under constant shaking. Then, the cells were pelleted by centrifugation at 5000 rpm for 5 min at room temperature. Then, the pellet was washed twice with sterile water. Cells were resuspended in 0.5 ml of lysis buffer (300 mM sorbitol, 10 mM Tris-HCl pH 7.4, 500 mM NaCl, 5 mM MgCl 2 , 5 mM ethylenediamine tetraacetic acid) plus protease inhibitor cocktail (Roche). Cells lysis was performed by vortexing four times for 60 s using glass beads. The supernatant was collected in an eppendorf tube; 1% Triton X-100 was added and mixed by vortexing for 30 s. Then, the sample was centrifuged at 14 000 rpm at 4°C for 15 min. Finally, the supernatant was collected in a new tube and protein concentration was determined using a Bradford Biorad assay (BioRad). Immunoprecipitation was carried out from 4 mg of total proteins that were incubated overnight with 30 µl of FLAG-M2 agarose beads (Sigma) at 4°C in a rotating wheel. Thereafter, the beads were pelleted at 4000 rpm for 3 min at 4°C. The supernatant was removed and the beads were washed four times with 1 ml of Binding Buffer G (50 mM TrisHCl pH 7.4, 250 mM NaCl, 50 mM NaF, 0.1% NP40). Finally, 20 µl loading buffer was added and the samples were treated at 70°C for 2 min. Then, samples were electrophoresed on a 4% acrylamide gel and transferred on a polyvinylidene difluoride (PVDF) membrane (GE Healthcare) for 17 h at 120 mA. In parallel, 100 µg of total protein were loaded. BRCA2p was analysed with anti-Flag diluted 1:1000 antibody (Sigma). Signal detection was performed using an anti-mouse horseradish peroxidase-linked antibody (Santa Cruz Biotechnology, Inc.) using the Supersignal Kit (Pierce).
Immunofluorescence Cells were grown overnight by shaking incubation at 30°C in selective medium URA-glucose, then induced in SC-URA containing 4% galactose for 17-24 h to optimise protein expression levels. Then they were treated with different doses of MMS in 5 ml of selective medium with galactose for 3-4 h. Cells were washed in water, centrifuged at 4500 rpm for 5 min and then fixed in phosphatebuffered saline (PBS) with 4% formaldehyde for 1 h at 30°C. After washing them twice in PBS, they were incubated in a Zymoliase Buffer (Zymoliase 70U, PEM buffer (Na-PIPES, EGTA, Mg 2 SO 4 , pH 6.8), 1 M sorbitol, 0.1% 2-mercaptoethanol) for at least 90 min, reading the optical density 600 every 30 min to follow the process. Spheroplasts were washed twice in PEM buffer plus 1.2 M sorbitol (PEMS) and stored at 4°C for a few days. Spheroplasts were seeded on a slide previously treated with 0.1% poly-l-lysine, let the drop for 30 min and then fixed for 5 min with 2% para-formaldehyde in PBS. They were then incubated in 0.7% Triton X-100/PEM for 3 min and blocked in 1% bovine serum albumin (BSA) in PEM for 1 h. Primary polyclonal antibody anti-BRCA2 (Santa Cruz, Sc8326) was incubated overnight at 4°C at the working dilution of 1:200 in 1% BSA in PEM. Anti-rabbit 633-conjugated secondary antibody (VALE) was used 1:600 in 1% BSA in PEM for 1 h at RT. Then cells were washed three times in 0.1% Triton, 1% BSA in PEM and covered by coverslips closed with Vectashield and 10 µM Hoescht to stain the DNA. Rad51-YFP foci, Rad52-YFP foci and BRCA2 were visualised with the TCS SL laser-scanning confocal microscope (Leica Microsystems, Milan, Italy) equipped with galvanometric stage using a 63X/1.4 NA HCX PL APO oil immersion objective, with typical x and y-step values of 0.150 µm. An Ar laser was used for YFP (= 514 nm) and a He-Ne laser for Alexa-633 (= 633 nm) excitation, with laser powers adjusted to maximise dynamic range and to avoid image saturation. Fluorescence emission was collected according to emission spectra. For the two-colour analysis, a sequential image acquisition was used to reduce crosstalk between different signals below 5%. Multi-channel images were then assembled in ImageJ (NIH). Moreover, Rad51 and Rad52 foci were visualised and counted for at least 700 cells each samples.
Recombination assay
The RS112 strain was constructed from the haploid RSY6 and consequently carries the same intra-chromosomal recombination substrate as RSY6 (29) . This substrate consists of two his3 alleles, one with a deletion at the 3′ end and the other with a deletion at the 5′ end, that share 400 bp of homology. These two alleles are separated by the LEU2 marker and by the plasmid DNA sequence. An intra-chromosomal recombination event leads to HIS3 reversion and loss of LEU2 (Figure 2a) (29) . The diploid RS112 strain also contains the two alleles ade2-40 and ade2-101, located in two homologous chromosomes that allow the measurement of inter-chromosomal recombination events (Figure 2b) (30) . To determine the frequency of intra-chromosomal and inter-chromosomal recombinations, single colonies were inoculated into 5 ml of SC-URA-LEU medium and incubated at 30°C for 24 h. Thereafter, cultures were induced in rich medium containing 5% galactose for 4 h at 30°C under constant shaking. In parallel, yeast cells carrying the empty pYES2 vector were grown in galactose complete medium. Then, cells were washed twice, counted and appropriate numbers were plated onto complete medium to determine the number of vital cells and onto solid medium lacking histidine or adenine to determine the frequency of intra-chromosomal and inter-chromosomal recombinations, respectively. Results are reported as mean of at least four independent experiments ± standard deviation. Data are statistically analysed by the Student t-test comparing the recombination frequency to the negative control (pYES2, empty vector).
As previously reported, a significant increase in recombination higher than 2-fold as compared with the negative control has to be considered biologically relevant (12, 31) .
Results
In this study, we aimed to understand if the yeast S. cerevisiae is a good model to study the role of BRCA2 in DNA recombination and repair and to characterise the unclassified BRCA2 missense variants. Therefore, we have expressed the wild-type BRCA2 in yeast and determined the effect of BRCA2 on yeast homologous recombination, MMS-induced Rad51 and Rad52 foci and MMS sensitivity. Finally, we have also expressed several missense BRCA2 variants and determined the effect on yeast homologous recombination.
BRCA2 is expressed in yeast
Yeast cells carrying the pYES-BRCA2 plasmid were grown at 30°C under constant shaking for 17-24 h and then shifted in 5% galactose medium for 4-6 h. As the BRCA2 protein is very large, we checked first if the BRCA2 cDNA was efficiently transcribed by RT-PCR. We extracted the total RNA from the clones transformed with the plasmid carrying the BRCA2 alleles and performed RT-PCR as reported in the Materials and methods section. As shown in Figure 3a and 3b, BRCA2 wild type and the missense variants are transcribed. Although the pYES2 vector is widely used to produce high levels of exogenous proteins in yeast (http://tools.invitrogen.com/content/ sfs/manuals/pyes2man.pdf), we had very hard time to visualise the protein by western blot. Therefore, we extracted the total proteins from the yeast strains expressing BRCA2 wild type, the S286P and the G2748D variants and performed immunoprecipitation using the anti-flag antibody. Although the protein seems to degrade very easily, the results shown in Figure 3c indicated that yeast is able to express BRCA2. Moreover, we carried out immunofluorescence in order to visualise the BRCA2 protein inside the yeast cells. Results reported in the Figure 4a and 4b clearly confirm that yeast is able to express BRCA2. Interestingly, BRCA2 localises both in the nucleus and in the cytoplasm.
Expression of wild-type BRCA2 increases homologous recombination and resistance to MMS in yeast and has no effect on number of nuclear foci
As BRCA2 is mainly involved in homologous recombination, we determined whether the expression of BRCA2 wild type may affect the frequency of intra-and inter-chromosomal recombinations in yeast after 4-h induction in 5% galactose. The expression of BRCA2 wild type induced a highly significant (P < 0.001) increase in both intra-and interchromosomal recombinations; the increase was as much as 5.2-fold and 9.5-fold over the negative control (strain carrying the empty pYES2 grown in galactose) for intraand inter-chromosomal recombinations, respectively (Table  II) . BRCA2 has been reported to interact with RAD51 and participate in homologous recombination DNA repair (32) . In addition, Rad52 interacts with Rad51 and promotes both strand annealing and exchange (33) . We, therefore, checked whether BRCA2 expression may affect the number of MMSinduced Rad51 and/or Rad52 nuclear foci. The strains W8702 carrying the pYES-BRCA2 and the RSY12 carrying both pWJ1344 carrying the RAD52-YFP and the pYES-BRCA2 were grown in galactose for 4 h and then treated with MMS for 2 h to induce nuclear foci. Then, spheroplasts were fixed and the proteins were visualised as described in the Materials and methods section. MMS increased the number of cells carrying Rad51 and Rad52 foci although BRCA2 had no effect on the total number of rad51 and rad52 nuclear foci as compared with the control (Figure 4a and 4b) . BRCA2 is localised in the nucleus. Moreover, the expression of BRCA2 induced a statistically significant increase in the survival to MMS in both the W8702 and the RSY12 strains, as reported in the Table III . Fig. 2 . Recombination substrates of the RS112 strain of S. cerevisiae. The RS112 strain of S. cerevisiae contains two homologous recombination substrate allowing to measure two distinct homologous recombination events occurring within a chromosome (intra-chromosomal) and between two homologous chromosomes (inter-chromosomal). (A) The intra-chromosomal recombination event occurs between the two duplicated and differentially deleted his3 alleles leading to the HIS3 reversion and the loss of LEU2. (B) The RS112 strain is also heteroallelic for ade2-40 and ade2-101 so that inter-chromosomal recombination events between homologues lead to ADE2 wild type.
Expression of the BRCA2 missense variants differentially affects yeast recombination
To investigate whether yeast can be exploited to develop a functional assay to characterise the BRCA2 missense variants not yet classified, we expressed two neutral BRCA2 variants and the deleterious variant G2748D and determined the effect on both intra-and inter-chromosomal yeast recombinations. The expression of the neutral variants A2951T and M1975T induced a significant increase (P < 0.05) in intra-chromosomal recombination (Figure 5a) . Specifically, the M1975T increased recombination by 1.9-fold as compared with the control; this value is statistically significant and very close to the biological relevancy (31) . Moreover, the other neutral variant increased recombination by 2.5-fold as compared with the negative control. The expression of deleterious missense variant G2748D did not increase both events in yeast (Figure 5a and 5b). The expression of the M927V, N1878K and R2108C also increased both homologous recombination events, although less significantly than the wild type (Figure 5a and 5b; Table II ). The variants A2951T and V3091I significantly increased intra-chromosomal recombination (Figure 5a ), but not inter-chromosomal recombination (Figure 5b ). On the other hand, the expression of the variants S286P, L1019V and N1878K significantly increased inter-chromosomal recombination (Figure 5b) . Moreover, expression of the variants T1011R and S2006R did not induce any recombination event in yeast (Figure 5a and 5b) . To confirm whether the increase in recombination was indeed due to the expression of BRCA2 variants, we performed experiments to determine the frequency of homologous recombination after growing the strain carrying the vector with the BRCA2 missense variants in glucose, where the protein expression is not taking place because the GAL1 promoter is repressed (15) . The frequency of both recombination events was not significantly different from that one determined in the strain carrying the empty pYES2 (Table  II) ; intra-chromosomal recombination was ranging from 1.27 to 1.66 × 10 4 vital cells, inter-chromosomal recombination was ranging from 0.43 to 0.91 × 10 -5 vital cells. In conclusion, the neutral variants increased recombination although at lesser extent than the wild type, whereas the deleterious variant did not affect recombination, differing from the result obtained when the BRCA2 wild type was expressed. Importantly, six out of eight selected variants that are classified as neutral (Table I) increased at least one recombination, event in yeast suggesting that yeast can be useful to develop a functional assay helping to classify BRCA2 missense variants. 4, 6, 8,10, 12, 14, 16, 18 , not retro-transcribed RNA was loaded to check for plasmid DNA contamination; lanes 3, 5, 7, 9, 11, 13, 15, 17, 19, samples corresponding to RNA extracted from cells carrying the variants M927V, T1011R, L1019V, A2951T, V3091I, R2108C, S2006R, N1878K and M1951T. (C) After galactose induction, total protein extracts were carried out as described. Immunoprecipitation was performed starting from 4 mg of total extract from cells expressing BRCA2 wild type, the S286P missense UCV and the pathogenic G2748D variant. The precipitate was loaded in the gel and hybridised with the anti-Flag antibody. In the lanes marked as IP, the immune precipitate from cells was loaded. In lane WCL, 100 µg of the total protein extract from BRCA2 wild type-expressing yeast cells was loaded.
Discussion
Although hundreds of BRCA2 truncating mutations have been associated with increased risk of cancer, the contribution of other BRCA2 variants remains largely undefined and is an important obstacle to identify individuals at risk of cancer and to provide appropriate health care options and counselling. Classification of BRCA2 variants as cancer predisposing or neutral has proven problematic because it is not known whether these subtle changes alter the function of the proteins sufficiently to predispose to cancer and there is insufficient information from family studies of these rare variants to allow classification using the likelihood model. Because of this problem, functional assays that assess the impact of amino acid changes on BRCA2 protein function have been proposed as an alternative approach to the classification of the cancer (11) .
BRCA2 deficiency is associated with a defect in homologous recombination and a high degree of chromosome instability, including chromosome breaks and radial chromosomes (4, 34, 35) . The direct interaction between BRCA2 and RAD51 and their co-localisation in nuclear foci after DNA damage was the first evidence for a role for BRCA2 within DNA double-strand break repair by homologous recombination (36) . In this study, we demonstrated that expression of the BRCA2 wild type confers a hyper-recombination phenotype, which could be exploited to develop a new functional assay to characterise UCVs. Moreover, we showed that BRCA2 may get involved in the DNA repair pathways because we demonstrated that the BRCA2 expressing yeast cells were more resistant to MMS than control. Recently, full-length BRCA2 was purified from yeast and mammalian cells (37) (38) (39) . Moreover, purified BRCA2 has been shown to bound yeast Rad51 in vitro (39) . This result was somehow expected, given the high homology between yeast and human RAD51 (39) . Therefore, yRAD51 and BRCA2 may also interact in the cells leading to a complex that could be less active in repairing endogenous DNA breaks. This may result in the accumulation of recombination intermediates that may explain the increase in recombination. The yeast strain used here contains two different recombination substrates that allow to measure the intra-chromosomal deletion events between DNA repeats and inter-chromosomal recombination events between two homologous chromosomes (31). These two events have been proposed to occur by different mechanisms and may require different genetic factors (40) . Previously, we have reported that the expression of human p53 affects homologous recombination in the same yeast strain confirming again that yeast provides an excellent genetic system to undercover the molecular mechanisms involved in cancer (41) . The effect of over-expression of BRCA2 in spontaneous and DNA double-strand break recombination repair was determined in human cells and gave quite contrasting results (10, 12, 20) . We have recently shown that the over-expression of full-length BRCA2 weakly affects homologous recombination in HeLa cells; on the other hand, BRCA2 pathogenic variants increased recombination in the same assay indicating that the HeLa recombination assay may help to classify missense variants (12) . However, BRCA2 over-expression stimulates DNA double-strand break repair by homologous recombination in human cells, whereas the pathogenic variants did not (10, 20) . Maybe, spontaneous and induced homologous recombination occurs by different mechanism in human cells; DNA double-strand breaks could not be required for spontaneous recombination in human cells, but it has been shown to initiate spontaneous recombination in yeast (42) . This could be the reason why BRCA2 increases spontaneous recombination in yeast and double-strand break repair in human cells. We previously showed that the expression of deleterious or potentially tumorigenic BRCA1 variants increases homologous recombination in the RS112 yeast suggesting that yeast genetics could be helpful in characterising potentially deleterious BRCA1 variants (15) .
To address whether yeast could also potentially be useful to distinguish a BRCA2 mutated protein from a neutral polymorphism, we have expressed two neutral (M1915T and A2951T) and one Then they were treated with 200 µg/ml MMS in 5 ml of galactose medium for 4 h at 30°C under shaking. Cells were washed in water, counted and plated in complete medium. Data are reported as mean of four independent experiments±standard deviation. Results were statistically analysed by comparing the MMS data using the Student's t-test. *P ≤ 0.005.
Fig. 5.
Effect of BRCA1 missense variant expression on yeast homologous recombination. Cells of the RS112 strain containing the plasmid expressing BRCA2 missense variants were first pre-grown in glucose. Then, cells were inoculated galactose medium for 24 h at 30°C. As described in the Materials and methods section, cells were counted and plated to score for cell-surviving fraction, the frequency of HIS3 intra-chromosomal recombination and ADE2 inter-chromosomal recombination. (A) Effect of BRCA2 protein expression on intra-chromosomal recombination. (B) Effect of BRCA2 protein expression on inter-chromosomal recombination. Data are reported as mean of 4-6 independent experiments ± standard deviation. Results were statistically analysed using the Student's t-test. *P < 0.05, **P < 0.005.
BRCA2 pathogenic variant G2748D. The neutral M1915T and A2951T variants indeed significantly increased one homologous recombination event in yeast although at lower level than the wild type. On the other end, the pathogenic variant G2748D did not increase HR in yeast and, consequently, confers a phenotype very different from the wild-type BRCA2. We selected eight variants that are classified as not deleterious (class 0) by in silico methods. We determined the effect of the expression of these variants on yeast recombination and we showed that six out of eight BRCA2 variants are able to induce at least one recombination event in our assay. These results may suggest that the variants that increase HR in our system are presumably not deleterious because they confer the same phenotype as the BRCA2 wild type. This may indicate that yeast could be a very promising genetic system to characterise BRCA2 missense variants and to understand the genetic basis of BRCA2-driven cancer.
